These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1097 related articles for article (PubMed ID: 32687917)
1. An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. Jamwal S; Gautam A; Elsworth J; Kumar M; Chawla R; Kumar P Life Sci; 2020 Sep; 257():118105. PubMed ID: 32687917 [TBL] [Abstract][Full Text] [Related]
2. Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past. Shah VK; Firmal P; Alam A; Ganguly D; Chattopadhyay S Front Immunol; 2020; 11():1949. PubMed ID: 32849654 [TBL] [Abstract][Full Text] [Related]
4. Contribution of monocytes and macrophages to the local tissue inflammation and cytokine storm in COVID-19: Lessons from SARS and MERS, and potential therapeutic interventions. Jafarzadeh A; Chauhan P; Saha B; Jafarzadeh S; Nemati M Life Sci; 2020 Sep; 257():118102. PubMed ID: 32687918 [TBL] [Abstract][Full Text] [Related]
5. [Repurposing of chlorpromazine in COVID-19 treatment: the reCoVery study]. Plaze M; Attali D; Petit AC; Blatzer M; Simon-Loriere E; Vinckier F; Cachia A; Chrétien F; Gaillard R Encephale; 2020 Jun; 46(3S):S35-S39. PubMed ID: 32387014 [TBL] [Abstract][Full Text] [Related]
6. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development. Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406 [TBL] [Abstract][Full Text] [Related]
7. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Lin L; Lu L; Cao W; Li T Emerg Microbes Infect; 2020 Dec; 9(1):727-732. PubMed ID: 32196410 [TBL] [Abstract][Full Text] [Related]
8. Expanded Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) as a Therapeutic Strategy in Managing Critically Ill COVID-19 Patients: The Case for Compassionate Use. Atluri S; Manchikanti L; Hirsch JA Pain Physician; 2020 Mar; 23(2):E71-E83. PubMed ID: 32214286 [TBL] [Abstract][Full Text] [Related]
9. Highlight of Immune Pathogenic Response and Hematopathologic Effect in SARS-CoV, MERS-CoV, and SARS-Cov-2 Infection. Liang Y; Wang ML; Chien CS; Yarmishyn AA; Yang YP; Lai WY; Luo YH; Lin YT; Chen YJ; Chang PC; Chiou SH Front Immunol; 2020; 11():1022. PubMed ID: 32574260 [TBL] [Abstract][Full Text] [Related]
11. Progress in Studies on Structural and Remedial Aspects of Newly Born Coronavirus, SARS-CoV-2. Gupta SP Curr Top Med Chem; 2020; 20(26):2362-2378. PubMed ID: 32962613 [TBL] [Abstract][Full Text] [Related]
12. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future]. Ye ZW; Jin DY Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053 [TBL] [Abstract][Full Text] [Related]
13. Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Ahmed-Hassan H; Sisson B; Shukla RK; Wijewantha Y; Funderburg NT; Li Z; Hayes D; Demberg T; Liyanage NPM Front Immunol; 2020; 11():1979. PubMed ID: 32973803 [TBL] [Abstract][Full Text] [Related]
14. Severe COVID-19: what have we learned with the immunopathogenesis? Bordallo B; Bellas M; Cortez AF; Vieira M; Pinheiro M Adv Rheumatol; 2020 Sep; 60(1):50. PubMed ID: 32962761 [TBL] [Abstract][Full Text] [Related]
15. Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial. Eckhardt CM; Cummings MJ; Rajagopalan KN; Borden S; Bitan ZC; Wolf A; Kantor A; Briese T; Meyer BJ; Jacobson SD; Scotto D; Mishra N; Philip NM; Stotler BA; Schwartz J; Shaz B; Spitalnik SL; Eisenberger A; Hod EA; Justman J; Cheung K; Lipkin WI; O'Donnell MR Trials; 2020 Jun; 21(1):499. PubMed ID: 32513308 [TBL] [Abstract][Full Text] [Related]
16. Biological, clinical and epidemiological features of COVID-19, SARS and MERS and AutoDock simulation of ACE2. Zhang XY; Huang HJ; Zhuang DL; Nasser MI; Yang MH; Zhu P; Zhao MY Infect Dis Poverty; 2020 Jul; 9(1):99. PubMed ID: 32690096 [TBL] [Abstract][Full Text] [Related]
17. Drug Discovery Strategies for SARS-CoV-2. Shyr ZA; Gorshkov K; Chen CZ; Zheng W J Pharmacol Exp Ther; 2020 Oct; 375(1):127-138. PubMed ID: 32723801 [TBL] [Abstract][Full Text] [Related]
18. COVID-19: The Immune Responses and Clinical Therapy Candidates. Zhand S; Saghaeian Jazi M; Mohammadi S; Tarighati Rasekhi R; Rostamian G; Kalani MR; Rostamian A; George J; Douglas MW Int J Mol Sci; 2020 Aug; 21(15):. PubMed ID: 32756480 [TBL] [Abstract][Full Text] [Related]
19. COVID-19 Vaccine: A comprehensive status report. Kaur SP; Gupta V Virus Res; 2020 Oct; 288():198114. PubMed ID: 32800805 [TBL] [Abstract][Full Text] [Related]
20. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2. Patil AM; Göthert JR; Khairnar V Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]